Background: Cardiogenic shock (CS) exhibits high (~50%) in-hospital mortality. The recently published Extracorporeal life Support in Cardiogenic Shock (ECLS-SHOCK) trial demonstrated the neutral effects of the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) on all-cause death, as well as on all secondary outcomes in subjects presenting with myocardial-infarction (MI)-related CS. Here, we compared ECLS-SHOCK eligibility criteria with a real-world cohort of CS patients. Methods and Results: ECLS-SHOCK eligibility criteria were applied to a prospective single-center CS registry (the PREPARE CS registry) consisting of 557 patients who were consecutively admitted to the catheterization laboratory (cath lab) of the Medical University of Graz, Austria, due to CS (SCAI C-E). Overall use of mechanical circulatory support (MCS) in this cohort was 19%. Sixty-nine percent of the entire cohort had MI-related CS, 38% of whom would have met ECLS-SHOCK eligibility criteria, thus representing only 27% of the PREPARE CS registry. Exclusion from the ECLS-SHOCK trial was based on patients with initial lactate values below 3 mmol/L (n = 168; 43.6%), aged over 80 years (n = 65; 16.9%), and with a duration of cardiopulmonary resuscitation (CPR) exceeding 45 min (n = 22; 5.7%). The 30-day mortality of patients of the PREPARE CS registry who met the ECLS-SHOCK eligibility criteria was 57.0%, compared to 48.4% of patients in the ECLS-SHOCK trial. The patients’ baseline characteristics, however, differed considerably with respect to type of infarction, age, and gender. Conclusions: In a real-world cohort of patients with MI-related CS, only 38% of patients met the eligibility criteria of the ECLS-SHOCK trial. Thus, the impact of the use of VA-ECMO on outcome parameters in MI-related CS, as observed in the ECLS-SHOCK trial, may differ in a more heterogeneous real-world CS population of the PREPARE CS registry.
28 October 2025 in JACC: Cardiovascular Interventions
Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder causing myocardial hypertrophy, sometimes leading to mid‐cavity obstruction (MCO), which can be underdiagnosed based solely on noninvasive imaging. Case summary: A 52‐year‐old male with exertional dyspnea and chest pain showed apical hypertrophy on echocardiography, with a mid‐cavity gradient of 27 mmHg at rest and 39 mmHg during Valsalva. MRI confirmed nonischemic late gadolinium enhancement. Invasive dual‐catheterization detected a midventricular gradient of 57 mmHg, rising to 73 mmHg postprovocation. Coronary artery disease was excluded. The patient was managed with beta‐blockers, mavacamten, and aerobic training. Discussion: This case highlights the importance of invasive hemodynamic assessment in diagnosing dynamic MCO, which may be underestimated on echocardiography. Provocation testing and simultaneous pressure measurements aid in accurate diagnosis and individualized therapy. Take‐Home Messages: Invasive assessment is crucial for detecting dynamic MCO in HCM. Myosin inhibitors may offer a novel therapeutic option.